Cure-IO Platform
At the centre of Curenetics sits the Cure-IO platform, our secure, continuously learning computational platform and operating system for immuno-oncology.
Cure-IO underpins the delivery of our immunotherapy response prediction test across all Curenetics offerings and provides a common intelligence layer that supports different routes to market. These include direct engagement with patients through platforms such as OnceraPLUS, clinician and hospital-facing solutions, and collaborations with pharma and CRO partners, each tailored to the needs of its audience while delivering the same core predictive capability.
As the test is deployed, Cure-IO securely learns from aggregated and consented interactions across these channels, continuously refining its predictive performance.
In this way, each offering both commercialises and strengthens the platform, while Cure-IO ensures scientific consistency, security, and scalability across Curenetics.
Curenetics Business Model
Patients
Through our direct-to-patient offering, including the OnceraPLUS platform, Curenetics delivers its immunotherapy response prediction test in a patient-centric, consent-driven environment. Patients are supported in accessing predictive insight relevant to their treatment journey, while CURE-IO securely processes and learns from aggregated patient-reported and outcome data to continuously strengthen the platform.
Clinician & Hospital
Our clinician and hospital offering provides access to the same immunotherapy response prediction test within real clinical settings. Powered by CURE-IO, the test is delivered as a computational decision-support tool that integrates predictive insight with clinical context, supporting treatment planning and outcome evaluation while maintaining the highest standards of data security and governance.
Pharma & CRO
For pharma and CRO partners, Curenetics offers the immunotherapy response prediction test through a research-focused channel supporting immuno-oncology discovery and development. Via CURE-IO, de-identified and aggregated data is transformed into predictive insight that enables patient stratification, biomarker discovery, and trial optimisation, all delivered through a secure, enterprise-ready platform.